Citrate-rich calcium-magnesium supplement and uses thereof

Patent metadata

Field	Value
Publication number	US-10092593-B2
Application number	US-201615288210-A
Country	US
Kind code	B2
Filing date	Oct 7, 2016
Priority date	Sep 4, 2012
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors.

First claim

The invention claimed is:

1. A method of reducing calciprotein particle (CPP) formation in an animal in need thereof, the method comprising:
administering to the animal a composition comprising:
from about 250 mg calcium to about 600 mg of calcium,
from about 70 mg magnesium to about 175 mg of magnesium,
at least 10 meq of citrate excess, and
at least 20 meq of total soluble citrate,
wherein the Ca/citrate molar ratio is from 0.4 to 0.7 and

wherein the CPP formation is reduced.

2. The method of claim 1 , wherein the serum magnesium is increased in the animal.

3. The method of claim 1 , wherein the serum phosphate is reduced in the animal.

4. The method of claim 1 , wherein hyperparathyroidism is reduced in the animal.

5. The method of claim 1 , wherein the composition comprises 300 mg of calcium, 122 mg of magnesium, 20 meq of citrate excess, and 45 meq of total soluble citrate, wherein the Ca/citrate molar ratio is about 0.5.

6. The method of claim 1 , wherein the composition consists essentially of 300 mg of calcium, 122 mg of magnesium, 20 meq of citrate excess, and 45 meq of total soluble citrate, wherein the Ca/citrate molar ratio is about 0.5.

7. The method of claim 1 , wherein the composition consists of 300 mg of calcium, 122 mg of magnesium, 20 meq of citrate excess, and 45 meq of total soluble citrate, wherein the Ca/citrate molar ratio is about 0.5.

8. The method of claim 1 , wherein the alkali load is increased in the animal.

9. The method of claim 1 , wherein the animal is a human.

10. The method of claim 9 , wherein the human has been diagnosed with chronic kidney disease (CKD).

11. The method of claim 10 , wherein the CKD is stage 5 CKD.

Assignees

• Univ Texas

Inventors

• Pak Charles Y C
• Sakhaee Khashayar
• Moe Orson W

Classifications

• A61P3/14

  for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title

• A61P19/10

  for osteoporosis · CPC title